Add to a list

Inactive Instrument

Northwest Biotherapeutics, Inc. Stock Other OTC

NWBO

US66737P6007

Biotechnology & Medical Research

OTC Markets Traded

Valuation: Northwest Biotherapeutics, Inc.

Market Cap	273M 238M 224M 204M 382M 26.18B 384M 2.68B 1.04B 13.32B 1.03B 1B 42.83B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	369M 321M 303M 276M 516M 35.39B 519M 3.63B 1.4B 18B 1.39B 1.36B 57.9B	EV / Sales 2026 *	-	EV / Sales 2027 *	10.2x
Free-Float	95.22%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news: Northwest Biotherapeutics, Inc.

08-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-16	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-16	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-14	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/10/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
24/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
27/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI

More news

Press Releases: Northwest Biotherapeutics, Inc.

08-15	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
08-06	Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company	PR
07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
07-02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
05-16	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ

More press releases

Managers and Directors: Northwest Biotherapeutics, Inc.

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

More insiders

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC.	-6.38%	-8.82%	-	-	282M
WUXI APPTEC CO., LTD.	-0.31%	+3.56%	+46.40%	+100.50%	70.89B
ARGENX SE	+0.39%	+1.82%	+38.93%	+77.73%	62.32B
INSMED INCORPORATED	-3.21%	-5.72%	-17.12%	+350.96%	27.07B
BIONTECH SE	-2.64%	-0.35%	-2.13%	-15.04%	24.78B
GENMAB A/S	+0.71%	+8.50%	+27.76%	-15.29%	20.59B
PHARMAESSENTIA CORPORATION	-1.26%	-10.61%	+170.72%	+290.48%	15.52B
EXELIXIS, INC.	-0.22%	+1.62%	+44.31%	+167.58%	14.49B
SUMMIT THERAPEUTICS INC.	+0.73%	+5.00%	-1.33%	+854.55%	14.14B
MADRIGAL PHARMACEUTICALS, INC.	-0.54%	-0.30%	+27.33%	+202.19%	12.35B
Average	-1.16%	+1.68%	+37.21%	+223.74%	29.13B
Weighted average by Cap.	-0.54%	+1.39%	+35.79%	+161.34%

	2026 *	2027 *
Net sales	-	38.93M 33.9M 32M 29.07M 54.44M 3.73B 54.71M 383M 148M 1.9B 146M 143M 6.11B
Net income	-	-
Net Debt	96.08M 83.65M 78.96M 71.74M 134M 9.21B 135M 944M 365M 4.68B 361M 353M 15.07B	125M 109M 103M 93.29M 175M 11.98B 176M 1.23B 474M 6.09B 469M 459M 19.6B

Northwest Biotherapeutics, Inc. Stock Other OTC

Stocks

NWBO

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc.

Latest news: Northwest Biotherapeutics, Inc.

Press Releases: Northwest Biotherapeutics, Inc.

Quotes and Performance

Managers and Directors: Northwest Biotherapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile